The medical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to provide a significant substantial reduction in body weight and enhance metabolic heal